Explore our sister journals here.

Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIRx Med

Date Submitted: Sep 9, 2021
Date Accepted: Sep 18, 2021

The final, peer-reviewed published version of this preprint can be found here:

Peer Review of “Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study”

Anonymous RC

Peer Review of “Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study”

JMIRx Med 2021;2(3):e33499

DOI: 10.2196/33499

PMCID: 10414311

Peer Review of "Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study" (ms#29638)

  • Reviewer CY Anonymous

ABSTRACT

This is a peer review report associated with ms#29638


 Citation

Please cite as:

Anonymous RC

Peer Review of “Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study”

JMIRx Med 2021;2(3):e33499

DOI: 10.2196/33499

PMCID: 10414311

Per the author's request the PDF is not available.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.